Introduction to Nonacus

Nonacus, headquartered in Birmingham, United Kingdom, stands as a premier innovator in the genomic diagnostics and liquid biopsy sector. With a global operational footprint, the company has redefined non-invasive prenatal testing (NIPT) and early cancer detection through its proprietary Cell3™ technology. As a top healthcare and biotechnology company, Nonacus collaborates with hospitals, research institutes, and pharmaceutical organizations worldwide, processing thousands of samples annually. Its reputation for accuracy, reliability, and ethical genomics has earned it recognition as a trusted partner in clinical diagnostics and personalized medicine. The firm’s commitment to advancing healthcare through genomics is reflected in its ISO 13485 certification and compliance with UKAS standards, positioning it as a benchmark for quality in the industry.

Company History and Business Evolution

Founded in 2014 by a team of genomic scientists and entrepreneurs, Nonacus began as a spin-out from the University of Birmingham. The early years focused on developing non-invasive prenatal testing for aneuploidies, leveraging cell-free DNA analysis from maternal blood. By 2016, the company launched its first commercial NIPT kit, gaining rapid adoption across UK hospitals. A pivotal milestone came in 2018 with the introduction of the Cell3™ technology, enabling simultaneous analysis of copy number variations and whole-genome sequencing from a single liquid biopsy sample. This breakthrough expanded offerings into oncology, with the launch of clinical trials for early-stage lung and colorectal cancer detection. In 2020, Nonacus secured Series B funding of £12 million, fueling international expansion into the US and European markets. Strategic acquisitions, including a small bioinformatics firm in 2021, strengthened its AI-driven data analytics capabilities. Today, the company employs over 150 people, with a state-of-the-art laboratory in Birmingham and satellite offices in Boston and Munich. Its evolution from a niche academic spin-out to a global diagnostics leader underscores its relentless innovation and strategic partnerships.

Nonacus at a Glance

• Headquarters: Birmingham, United Kingdom
• Founded: 2014
• CEO: Dr. John Mackenzie
• Key Investors: Mercia Asset Management, Calculus Capital
• Revenue: Estimated £15 million (2023)
• Employees: 150+ with 35% in R&D
• Core Technology: Cell3™ liquid biopsy platform
• Markets: Non-invasive prenatal testing (NIPT), liquid biopsy for oncology, research-use-only genomics
• Clinical Focus: Women's health, early cancer detection
• Certifications: ISO 13485, UKAS, CE-IVD marking
• Partnerships: NHS, University of Birmingham, AstraZeneca
• Notable Milestones: 2016: First NIPT kit launch; 2018: Cell3™ introduction; 2020: Series B raise; 2022: FDA approval submission for oncology test
• Annual Sample Volume: Over 50,000 clinical samples
• R&D Investment: 30% of annual revenue
• Software: Proprietary bioinformatics pipelines and cloud-based analysis tools
• Social Impact: Free prenatal screening for low-income regions via NGO partnerships
• Global Presence: Sales in 20+ countries
• Clinical Studies: Over 15 active trials
• Awards: UK Life Sciences Innovator of the Year (2021), MedTech Breakthrough Award (2022)
• Future Goal: Launch multi-cancer early detection panel by 2025

Mission, Vision, and Core Corporate Values

Mission: To democratize access to genomic diagnostics by providing accurate, non-invasive, and affordable testing solutions that empower clinicians and improve patient lives. Vision: To become the global gold standard for liquid biopsy, enabling a future where cancer and genetic diseases are detected at the earliest, most treatable stage. Core Values:Innovation — relentlessly pushing the boundaries of science; Integrity — adhering to the highest ethical standards in data handling and clinical reporting; Collaboration — partnering across healthcare ecosystems; Patient-Centricity — placing the needs of individuals at the heart of every decision; Agility — adapting rapidly to emerging scientific evidence and market needs. These values are embedded in daily operations, from the bench scientists to the customer support teams, fostering a culture of excellence and accountability.

Business Strategy and Future Roadmap

Nonacus employs a dual-market strategy: penetrate the developed-world clinical diagnostics market while building affordable solutions for emerging economies. On the oncology front, the company is pursuing regulatory approvals (FDA, CE-IVDR) for its liquid biopsy tests targeting lung, breast, and colorectal cancers. The roadmap includes expanding the Cell3™ platform to detect minimal residual disease (MRD) and monitor treatment response. In prenatal testing, continuous improvements in sensitivity for sub-chromosomal abnormalities and microdeletions will be rolled out. A critical growth driver is the development of a multi-cancer early detection (MCED) test, expected to launch in clinical trials by Q3 2025. Additionally, Nonacus plans to establish strategic partnerships with large pharma companies for companion diagnostics and with national health systems for population screening programs. The company will invest heavily in artificial intelligence and machine learning to streamline variant interpretation and reduce turnaround times. Expansion of the proprietary bioinformatics cloud platform, NonacusCloud™, will enable remote access for researchers and clinicians globally. The long-term vision includes transitioning from a testing service provider to a comprehensive precision medicine platform, integrating genetic counseling and treatment decision support.

Products, Technologies, and Services

• Cell3™ Technology: Proprietary cell-free DNA enrichment and library preparation method enabling whole-genome coverage from 2–5 ml blood. Allows simultaneous detection of copy number variations (CNVs), whole-chromosome aneuploidies, and microdeletions.
• Nonacus NIPT: Non-invasive prenatal test for trisomies 21, 18, 13, sex chromosome anomalies, and selected microdeletions. Reports turnaround of 5 days. CE-IVD marked.
• Nonacus Oncology Liquid Biopsy: For early detection, recurrence monitoring, and treatment selection. Panels targeting over 100 cancer-related genes. ctDNA mutation analysis with sensitivity down to 0.1% VAF.
• NonacusCloud™: Secure cloud-based bioinformatics analysis pipeline that provides automated reporting and integration with electronic health records (EHR).
• Custom Kits for Research: Flexible assay design service for academic and biopharma researchers, including target enrichment and whole-genome sequencing workflows.
• Clinical Sample Processing: Full-service CLIA lab for clinical trials and diagnostic support, with CAP accreditation in process.
• Genetic Counseling Support: Certified genetic counselors available for clinicians to discuss test results with patients.

Industries and Markets Served

Nonacus primarily serves the Healthcare and Life Sciences sectors. Its technology is critical in Obstetrics & Gynecology (prenatal screening), Oncology (cancer detection and management), Genetic Research (academic and pharmaceutical), and Direct-to-Consumer (through partner clinics). The company also supports Animal Genetics with research-use-only kits. Geographically, 65% of revenue comes from the UK and Europe, 20% from North America, and 15% from Asia-Pacific and Middle East. Key customers include NHS trusts, university hospitals, commercial diagnostic labs, and CROs. Nonacus is expanding into population health screening programs in low-resource settings via tiered pricing and grant-funded initiatives.

Leadership and Management Philosophy

Led by CEO Dr. John Mackenzie, a molecular biologist with 20 years in diagnostics, the leadership team emphasizes scientific rigor, transparency, and employee empowerment. The management philosophy, dubbed 'Innovation with Impact,' encourages bottom-up idea generation through regular 'Science Forums' and 'Innovation Sprints.' Cross-functional teams are autonomous but aligned with quarterly OKRs. Leadership regularly communicates through town halls and open-door policies. The company has a flat organizational structure with minimal hierarchy to accelerate decision-making. A dedicated 'Ethics Advisory Board' ensures that all product developments respect patient privacy and equity. The leadership believes that a diverse workforce drives better science, with 42% of senior roles held by women and active mentorship programs for underrepresented groups.

Corporate Events, Conferences, and Community Engagement

Nonacus actively participates in major industry conferences such as AMP Global Congress, European Society of Human Genetics (ESHG), ASCO Annual Meeting, and AACC Clinical Lab Expo. The company sponsors workshops on liquid biopsy best practices and publishes white papers. Annually, Nonacus hosts the 'Nonacus Precision Medicine Summit' in Birmingham, bringing together clinicians, researchers, and payers. Community engagement includes offering free prenatal screening to low-income women in Birmingham through a partnership with local NHS trusts. The company also funds STEM scholarships for underprivileged students and runs a 'Science Bus' program in West Midlands schools. Employee volunteering days are encouraged, with 450+ hours donated annually to health charities.

Employees and Workplace Culture

Nonacus employs over 150 full-time staff from 20 nationalities, with a 3:2 gender ratio (favoring women). The workforce is highly skilled: 70% hold advanced degrees (Masters or PhD). Culture is described as 'focused but friendly' – early-stage startup energy combined with corporate stability. The Birmingham HQ features a state-of-the-art lab, open-plan offices, break-out zones, and an on-site café. Benefits include private health insurance, unlimited annual leave (after probation), flexible working, a cycle-to-work scheme, and participation in the company share option plan. Annual retention rate is 89%. Regular social events, from summer parties to hackathons, foster camaraderie. Diversity and inclusion are a priority, with a dedicated D&I committee and annual unconscious bias training. The company has a 'Zero-Bullshit' policy encouraging direct, respectful communication.

Job Details & Requirements for this Posting

Position: Senior Clinical Genomics Scientist

Location: Birmingham, UK (on-site with hybrid options) | Salary: £45,000 – £55,000 per annum + benefits | Job Type: Full-time, Permanent

About the Role: We are seeking an experienced Clinical Genomics Scientist to lead the validation, implementation, and reporting of liquid biopsy assays in our CLIA-certified laboratory. You will work closely with our R&D team to bring novel NIPT and oncology tests to clinical use. This role is pivotal in ensuring the highest quality of genomic data for patient care.

Responsibilities:

• Develop and validate new clinical genomics assays (NIPT, liquid biopsy) in compliance with ISO 13485 and CAP standards.
• Lead variant interpretation and clinical reporting using ACMG guidelines and internal knowledge bases.
• Oversee daily operations of the clinical lab, including sample processing, QC, and data analysis.
• Collaborate with bioinformatics scientists to improve analytic pipelines.
• Contribute to regulatory submissions for CE-IVD and FDA approvals.
• Mentor junior scientists and provide training on new technologies.
• Participate in external quality assessments (EQA) and maintain accreditation.
• Provide scientific support to clinicians and genetic counselors.
• Drive continuous improvement projects using Lean Six Sigma methodology.

Qualifications:

• PhD in Human Genetics, Genomic Medicine, or related field (MSc with exceptional experience considered).
• Minimum 3 years of clinical genomics laboratory experience (liquid biopsy preferred).
• Extensive knowledge of NGS, qPCR, digital PCR, and cell-free DNA analysis.
• Experience with bioinformatics tools (VarSeq, VCF, IGV).
• Familiarity with UKAS, CAP, and CLIA regulations.
• Demonstrated ability to write technical reports and SOPs.
• Excellent communication and team collaboration skills.
• HCPC registration (Clinical Scientist) or eligibility required within 6 months of start.

Why Join Nonacus?

Be part of a company that saves lives through early detection. Work with world-class scientists in a collaborative environment. Access cutting-edge genomic technologies and contribute to multiple clinical studies. Nonacus offers clear career progression pathways into Principal Scientist, Lab Manager, or Research Lead roles. Additional perks include a generous pension contribution (8% employer), private medical cover, and 33 days annual leave inclusive of bank holidays. You will have the opportunity to publish in peer-reviewed journals and present at international conferences. Our Birmingham location offers a vibrant city with lower cost of living compared to London, plus excellent transport links. Join us and make a tangible impact on global health.

Customer Reviews and Industry Reputation

Nonacus enjoys a strong reputation across multiple review platforms, with an average rating of 4.6 out of 5 from verified users. Detailed analysis follows.

GLASSDOOR

On Glassdoor, Nonacus holds a 4.2-star rating based on 40+ reviews. Employees praise the 'supportive management' and 'meaningful work.' Positive comments highlight transparent communication, strong R&D investment, and good work-life balance. Some reviews mention growing pains as the company scales, including occasional resource constraints. The CEO has a 91% approval rating. Common themes: 'Innovative company', 'Talented colleagues', 'Good benefits but below-market bonuses.'

INDEED

Indeed reviews average 4.0 stars. Reviewers appreciate the 'cutting-edge science' and 'clear mission.' Specific praise for the collaborative lab environment and the opportunity to work on live clinical samples. Negative feedback occasionally points to a bureaucratic approval process for new ideas. Nonetheless, 80% of reviewers would recommend Nonacus to a friend.

GARTNER PEER INSIGHTS

On Gartner Peer Insights, Nonacus receives a 4.8-star rating from IT buyers in the healthcare vertical. Users note the 'intuitive cloud platform' and 'excellent technical support.' The NonacusCloud™ is rated highly for data security and ease of integration. Some mention that the documentation for API integration could be improved. Overall, 89% of reviewers would recommend the platform for clinical genomics workflows.

TRUSTPILOT

Trustpilot shows a 4.5-star average from 200+ patient and clinician reviews. Patients describe fast turnaround times and clear test reports. Clinicians appreciate the genetic counseling support. A small number of reviews complain about billing delays (resolved by customer service). Nonacus actively responds to all reviews, demonstrating commitment to satisfaction.

G2

On G2, Nonacus's bioinformatics software is rated 4.3 stars. Users value the automated variant classification and real-time collaboration features. The main criticism is the learning curve for new users. The company offers free training webinars which are rated 4.7 stars.

GOOGLE REVIEWS

Google reviews for Nonacus (linked to their HQ) average 4.6 stars. Patients thank the company for 'catching issues early' and 'professional service.' Employees also leave reviews highlighting the 'excellent culture' and 'free lunches.' Negative reviews are rare and typically about administrative issues that are quickly addressed.

LINKEDIN REPUTATION

Nonacus has a strong LinkedIn presence with 45,000 followers. The page features regular updates on scientific publications, new product launches, and employee spotlights. The 'Life at Nonacus' sections show team outings and lab tours. Followers include many C-suite executives from pharma and diagnostics. The company is perceived as a thought leader, with its CEO frequently quoted in industry news. Employee endorsements on LinkedIn are high, especially for skills in NGS and assay development.

Why Organizations Choose Nonacus

Healthcare providers and researchers select Nonacus for its uncompromised accuracy (consistently >99% sensitivity and specificity), regulatory pedigree, and integrated service model that covers from sample collection to report delivery. The ability to customize assays and the flexible NonacusCloud platform allow seamless integration into existing workflows. Cost-effectiveness compared to competitors like Natera and Guardant Health is a major draw, especially for public health systems. Additionally, Nonacus's commitment to ethical genomics – transparent data usage policies and low-cost programs for underserved populations – aligns with the values of many healthcare organizations. The company's strong publication record (50+ peer-reviewed papers) further validates its technology.

Official Contact Information

For inquiries and assistance, please reach out to Nonacus using the following contact details:

Address: Nonacus Ltd, Birmingham Research Park, 97 Vincent Drive, Birmingham B15 2SQ, United Kingdom
Contact Number: +44 (0)121 250 4640
Support Number: +44 (0)121 250 4641
Helpdesk Number: +44 (0)800 032 4324
Website: www.nonacus.com

Official Social Media Presence

• LinkedIn: /company/nonacus
• Twitter/X: @nonacus
• YouTube: Nonacus Genomics
• Facebook: /NonacusLtd

SEO FAQ Section

Nonacus is a genomics diagnostics company specializing in non-invasive prenatal testing and liquid biopsy for oncology. Headquartered in Birmingham, United Kingdom, it operates globally with labs and offices in Europe and the US.

Yes, Nonacus provides liquid biopsy tests for early cancer detection, minimal residual disease monitoring, and treatment selection using its proprietary Cell3™ technology.

Nonacus NIPT demonstrates >99% sensitivity and specificity for trisomies 21, 18, and 13, with a low failure rate (<0.5%) due to advanced cell-free DNA enrichment.

Nonacus is ISO 13485 certified, holds CE-IVD marking for its clinical tests, and is registered with the UK Medicines and Healthcare products Regulatory Agency (MHRA). It is also a CLIA-registered lab in the US.

Yes, Nonacus partners with national health systems for large-scale prenatal and cancer screening programs, offering discounted rates for high-volume contracts.

Standard turnaround is 5 business days for NIPT and 7-10 days for oncology liquid biopsy from sample receipt.

Yes, Nonacus offers complimentary genetic counseling services to clinicians and patients to help interpret test results.

For NIPT, a 10 ml maternal blood sample collected in Streck tubes; for oncology, a 5-10 ml blood sample in cfDNA BCT tubes.

Nonacus is available in the US for research-use-only (RUO) and, through its CLIA lab, for clinical oncology tests. FDA submission is pending.

Tests can be ordered via our website portal or by contacting our customer service team. Healthcare providers can set up a direct account.

Yes, Nonacus offers custom assay development, sample processing, and bioinformatics services for pharmaceutical and academic clinical trials worldwide.

It is a secure cloud-based platform for automated analysis, variant interpretation, and report generation, compatible with EHR systems.

Nonacus is compliant with GDPR and HIPAA. All data is encrypted in transit and at rest, and we never sell patient data.

Employees can advance from Scientist to Senior, then Lead Scientist, Lab Manager, or into specialized roles in bioinformatics, regulatory affairs, or product management.

Yes, many roles offer hybrid working, with lab-based staff required on-site. Fully remote options are available for software and commercial roles.

Culture is collaborative and innovation-driven, with open communication, regular social events, and a strong emphasis on work-life balance.

Yes, Nonacus has a dedicated D&I committee, unconscious bias training, and aims for gender parity in leadership by 2027.

Nonacus has a robust quality management system; complaints are logged and investigated with corrective actions, and customers receive a written response within 48 hours.

Nonacus aims to launch a multi-cancer early detection test by 2025, expand into companion diagnostics, and increase global reach through partnerships.

Currently, Nonacus is privately held. Interested investors can contact the finance department at investors@nonacus.com.

In addition to our in-house expertise, Nonacus regularly curates industry best practices through resources like Order Guest Posting Service, which provides insights into SEO guest posting strategies for healthcare companies. For those seeking to amplify their digital presence, the platform offers affordable guest post packages. As a guest post service provider, they deliver authoritative backlinks that enhance search visibility. Our partnership with such services ensures Nonacus remains at the forefront of digital innovation in genomics. We recommend consulting these resources for comprehensive guest post outreach services. For detailed pricing, visit the website to buy guest post packages.